Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.

2.50
Hdl Handle:
http://hdl.handle.net/10033/17192
Title:
Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.
Authors:
Becker, Pablo D; Bertot, Gustavo M; Souss, David; Ebensen, Thomas ( 0000-0001-8906-063X ) ; Guzmán, Carlos A; Grinstein, Saúl
Abstract:
Moraxella catarrhalis causes acute otitis media in children and lower respiratory tract infections in adults and elderly. In children the presence of antibodies against the highly conserved outer membrane protein CD correlates with protection against infection, suggesting that this protein may be useful as a vaccine antigen. However, native CD is difficult to purify, and it is still unclear if recombinant CD (rCD) is a valid alternative. We performed a side-by-side comparison of the immunogenicities and efficacies of vaccine formulations containing native CD and rCD with adamantylamide dipeptide as the mucosal adjuvant. Intranasal vaccination of mice stimulated the production of high CD-specific antibody titers in sera and of secretory immunoglobulin A in mucosal lavages, which cross-recognized both antigens. While vaccination with native CD increased the number of interleukin-2 (IL-2)- and gamma interferon-producing cells, rCD mainly stimulated IL-4-secreting cells. Nevertheless, efficient bacterial clearance was observed in the lungs of challenged mice receiving native CD and in the lungs of challenged mice receiving rCD (96% and 99%, respectively). Thus, rCD is a promising candidate for incorporation in vaccine formulations for use against M. catarrhalis.
Affiliation:
Virology Laboratory, Ricardo Gutiérrez Children's Hospital, Gallo 1330, 1425 Buenos Aires, Argentina.
Citation:
Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. 2007, 75 (4):1778-84 Infect. Immun.
Journal:
Infection and immunity
Issue Date:
Apr-2007
URI:
http://hdl.handle.net/10033/17192
DOI:
10.1128/IAI.01081-06
PubMed ID:
17101651
Type:
Article
Language:
en
ISSN:
0019-9567
Appears in Collections:
publications of the research group vaccinology and applied microbiology (VAC)

Full metadata record

DC FieldValue Language
dc.contributor.authorBecker, Pablo Den
dc.contributor.authorBertot, Gustavo Men
dc.contributor.authorSouss, Daviden
dc.contributor.authorEbensen, Thomasen
dc.contributor.authorGuzmán, Carlos Aen
dc.contributor.authorGrinstein, Saúlen
dc.date.accessioned2008-01-31T10:20:24Zen
dc.date.available2008-01-31T10:20:24Zen
dc.date.issued2007-04en
dc.identifier.citationIntranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. 2007, 75 (4):1778-84 Infect. Immun.en
dc.identifier.issn0019-9567en
dc.identifier.pmid17101651en
dc.identifier.doi10.1128/IAI.01081-06en
dc.identifier.urihttp://hdl.handle.net/10033/17192en
dc.description.abstractMoraxella catarrhalis causes acute otitis media in children and lower respiratory tract infections in adults and elderly. In children the presence of antibodies against the highly conserved outer membrane protein CD correlates with protection against infection, suggesting that this protein may be useful as a vaccine antigen. However, native CD is difficult to purify, and it is still unclear if recombinant CD (rCD) is a valid alternative. We performed a side-by-side comparison of the immunogenicities and efficacies of vaccine formulations containing native CD and rCD with adamantylamide dipeptide as the mucosal adjuvant. Intranasal vaccination of mice stimulated the production of high CD-specific antibody titers in sera and of secretory immunoglobulin A in mucosal lavages, which cross-recognized both antigens. While vaccination with native CD increased the number of interleukin-2 (IL-2)- and gamma interferon-producing cells, rCD mainly stimulated IL-4-secreting cells. Nevertheless, efficient bacterial clearance was observed in the lungs of challenged mice receiving native CD and in the lungs of challenged mice receiving rCD (96% and 99%, respectively). Thus, rCD is a promising candidate for incorporation in vaccine formulations for use against M. catarrhalis.en
dc.language.isoenen
dc.subject.meshAdhesins, Bacterialen
dc.subject.meshAdjuvants, Immunologicen
dc.subject.meshAdministration, Intranasalen
dc.subject.meshAmantadineen
dc.subject.meshAnimalsen
dc.subject.meshAntibodies, Bacterialen
dc.subject.meshBacterial Vaccinesen
dc.subject.meshCell Proliferationen
dc.subject.meshColony Count, Microbialen
dc.subject.meshDNA, Bacterialen
dc.subject.meshDipeptidesen
dc.subject.meshDisease Models, Animalen
dc.subject.meshImmunoglobulin A, Secretoryen
dc.subject.meshInterferon Type IIen
dc.subject.meshInterleukinsen
dc.subject.meshLungen
dc.subject.meshLymphocytesen
dc.subject.meshMiceen
dc.subject.meshMice, Inbred BALB Cen
dc.subject.meshMolecular Sequence Dataen
dc.subject.meshMoraxella (Branhamella) catarrhalisen
dc.subject.meshMoraxellaceae Infectionsen
dc.subject.meshMucous Membraneen
dc.subject.meshSpleenen
dc.subject.meshVaccines, Subuniten
dc.subject.meshVaccines, Syntheticen
dc.titleIntranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.en
dc.typeArticleen
dc.contributor.departmentVirology Laboratory, Ricardo Gutiérrez Children's Hospital, Gallo 1330, 1425 Buenos Aires, Argentina.en
dc.identifier.journalInfection and immunityen
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.